← Leaderboards
Peter S Hammerman
Dana-Farber Cancer Inst
$2,524,867
Attributed
$2,834,993
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $746.3K · FY2012–19$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,834,993 · 4
By mechanism
P01$1,044,621 · 1
R01$1,006,928 · 2
K08$783,444 · 1
Top collaborators
- John V. Heymach1 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Nathanael Schiander Gray$36,761,550
- David A Barbie$12,794,638
- Kenneth C Anderson$25,995,373
- Matthew Gilbert Oser$2,847,213
- David Kozono$1,824,190
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseKinase InhibitorInhibitor/AntagonistResistanceMutationFibroblast Growth Factor ReceptorsTherapeutic TargetMalignant NeoplasmsMalignant Neoplasm Of LungPharmaceutical PreparationsEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorCancer Cell LinePhosphotransferasesCell LineCancer CellMutantMolecularTreatment ResponseProteinsCancer TherapyDrug ResistanceClinical TrialsClinicMouse Model
Grant awards (10)
Project 3: Targeting transcriptional mechanisms of therapeutic resistance in non-small cell lung cancer.$348,207
P01 · FY2019 · CA · contact PI
Project 3: Targeting transcriptional mechanisms of therapeutic resistance in non-small cell lung cancer.$348,207
P01 · FY2018 · CA · contact PI
Project 3: Targeting transcriptional mechanisms of therapeutic resistance in non-small cell lung cancer.$348,207
P01 · FY2017 · CA · contact PI
Therapeutic approaches for LKB1-deficient non-small cell lung cancer$620,252
R01 · FY2016 · CA
Genomic Discovery and Targeted Therapeutics in Squamous Cell Lung Cancer$126,042
K08 · FY2016 · CA · contact PI
Therapeutic targeting of Fibroblast Growth Factor Receptors in Squamous Cancers$386,676
R01 · FY2015 · CA · contact PI
Genomic Discovery and Targeted Therapeutics in Squamous Cell Lung Cancer$126,042
K08 · FY2015 · CA · contact PI
Genomic Discovery and Targeted Therapeutics in Squamous Cell Lung Cancer$177,120
K08 · FY2014 · CA · contact PI
Genomic Discovery and Targeted Therapeutics in Squamous Cell Lung Cancer$177,120
K08 · FY2013 · CA · contact PI
Genomic Discovery and Targeted Therapeutics in Squamous Cell Lung Cancer$177,120
K08 · FY2012 · CA · contact PI